Gene

KIT

KIT proto-oncogene, receptor tyrosine kinase

Explore in graph →CI-GENE-00006972HGNC:6342 ENSG00000157404 NCBI 3815 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (312)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 201–250 of 312 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KIT S692L2
Imatinib	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	—	submitted	EID2494 Mutations within exons 13 and 14, which encode the ATP binding pocket of the kinase, alter the drug binding site.

Cohorts

Alteration frequency by cohort (130)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved130 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Acute Myeloid Leukemia (TCGA GDC, 2025) aml_tcga_gdc	Acute Myeloid Leukemia	Ssm	2	72	2.8%

Literature

Linked publications (44)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 44 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
· J Clin Oncol · 2003 · PMID 14645423 · validated civic_curation pubmed
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
· Eur J Cancer · 2006 · PMID 16624552 · validated civic_curation pubmed
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
· J Clin Oncol · 2006 · PMID 16954519 · validated civic_curation pubmed
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.
· Blood · 2006 · PMID 16384925 · validated civic_curation pubmed

KIT T417_D419delinsY1
Imatinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Sensitivity Response	2	accepted	EID2417 This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase II… (full text at CIViC) PMID 18955451 · Heinrich et al., 2008 · Open in CIViC	civic

KIT T417_D419delinsY1

Imatinib

Gastrointestinal Stromal Tumor

Predictive

Supports Sensitivity Response

accepted

EID2417

This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase II… (full text at CIViC)

PMID 18955451 · Heinrich et al., 2008 · Open in CIViC

KIT T670I6
Dasatinib	Solid NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4509 In an in vitro study of gastrointestinal tumors, the HEK-293 cells expressing KIT V559D (a known sensitizing mutation to dasatinib) and T670I co-mutation was found to have reduced sensitivity to dasat… (full text at CIViC) PMID 16046538 · Carter et al., 2005 · Open in CIViC	civic
Imatinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	3	accepted	EID2924 147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC) PMID 16954519 · Heinrich et al., 2006 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	5	accepted	EID7416 A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent gr… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Ponatinib + SunitinibSubstitutes	Gastrointestinal Stromal Tumor	Predictive	D	Does Not Support Resistance	5	accepted	EID7417 Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary ponatinib and sunitinib sensitizing mutation del 557-558, wh… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Regorafenib Anhydrous	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	4	accepted	EID4510 A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	D	Does Not Support Resistance	4	rejected	EID7399 Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary sunitinib-sensitizing mutation del 557-558 and secondary mut… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic

KIT V559D11
CHMFL-KIT-031	Gastrointestinal Stromal Tumor	Predictive	D	Supports Sensitivity Response	3	submitted	EID7870 A novel compound identified in a high-throughput screen is highly selective for KIT V559D in cell lines and mice models. In mice, there was a dose-dependent reduction in tumor size. PMID 29340041 · Yu et al., 2017 · Open in CIViC	civic
Dasatinib	Melanoma	Predictive	D	Supports Sensitivity Response	—	submitted	EID4107 In an in vitro study, Ba/F3 cells expressing KIT V559D mutation were found to have increased sensitivity to dasatinib (IC50: 22 nM). Sensitivity was determined by assessing cell proliferation, apopto… (full text at CIViC) PMID 17372901 · Antonescu et al., 2007 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	rejected	EID4114 In an in vitro study of gastrointestinal tumors, HEK-293 cells expressing KIT V559D mutation were found to have sensitivity to dasatinib treatment. (IC50: 8nM). Sensitivity was determined by assessin… (full text at CIViC) PMID 16046538 · Carter et al., 2005 · Open in CIViC	civic
Dasatinib + Imatinib + Nilotinib + SorafenibSubstitutes	Gastrointestinal Stromal Tumor	Predictive	D	Supports Sensitivity Response	4	submitted	EID3033 dasatinib inhibited cell growth of imatinib-sensitive KIT V559D with an IC50 of 27 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 63, 44, and 66 nmol/L, respectively. PMID 17699867 · Guo et al., 2007 · Open in CIViC	civic
Imatinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Sensitivity Response	3	accepted	EID3028 A patient with an uncontrolled relapse of c-kit-positive mesenchymal tumor in descending part of the duodenum had received 400mg Imatinib daily for more than 10 years at the time of publication. He re… (full text at CIViC) PMID 22114577 · Cameron et al., 2011 · Open in CIViC	civic
Dasatinib + Imatinib + PD-180970 + Sunitinib + TandutinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID3029 KIT(V559D) were expressed in HEK-293 cells (in vitro). Imatinib, BMS-354825 (dasatinib), PD-180970, MLN-518 (tandutinib), and SU-11248 bind variant V559D with high affinity (Kd =< 20 nM), and inhibit … (full text at CIViC) PMID 16046538 · Carter et al., 2005 · Open in CIViC	civic
Imatinib + Ponatinib + RegorafenibSubstitutes	Gastrointestinal Stromal Tumor	Predictive	D	Supports Sensitivity Response	2	accepted	EID4459 In an in vitro kinase study, a KIT V559D primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 36nmol/L vs. 640nmol/L), regorafenib (IC50: 57nmol/L vs. 533nmol/L), and ponatinib… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	—	submitted	EID4108 In a phase 1/2 trial of 97 gastrointestinal stromal tumor patients, patients with KIT exon 11 mutations (44/77) treated with sunitinib were associated with shorter progression free survival (5.1mo vs.… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	—	submitted	EID4110 In a retrospective study of 1124 sunitinib-treated gastrointestinal stromal tumor patients, patients with primary KIT exon 11 mutations (n=143) were associated with decreased progression free surviva… (full text at CIViC) PMID 26772734 · Reichardt et al., 2016 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	—	submitted	EID4109 In an in vitro study, a 32D cell line expressing KIT V559D mutation (overexpression) demonstrated increased sensitivity to sunitinib treatment (IC50: 2.0nM) compared to 32D cells expressing wild-type … (full text at CIViC) PMID 24205792 · Zhao et al., 2014 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	—	submitted	EID4592 In an in vitro study, a Ba/F3 cell line expressing KIT K558NP mutation (overexpression) demonstrated improved sensitivity to sunitinib treatment (IC50: 2nM vs. 8nM) compared to Ba/F3 cells expressing … (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic

KIT V560DEL3
Imatinib	Thymus CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	5	accepted	EID486 In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib. PMID 15201427 · Ströbel et al., 2004 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	D	Supports Sensitivity Response	—	submitted	EID2461 Molecular models predict that deletion of a portion of the juxtamembrane domain relieves steric hindrance and results in higher binding affinity for imatinib. PMID 21364689 · Pierotti et al., 2011 · Open in CIViC	civic
Imatinib Mesylate	Thymus CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID7359 Thymic Carcinoma with Overexpression of Mutated KIT (V560DEL) and the Response to Imatinib PMID 15201427 · Ströbel et al., 2004 · Open in CIViC	civic